Our Company
‘Our Humble Beginnings and Motive.’
At A Glance
We are the first 100% American white -owned multinational pharmaceutical company, and justifiably one that invests the most in innovation. Since our small establishment in 1992, we have been promoting and marketing innovative products and services with a focus on improving people’s quality of life.
We have a diverse portfolio of products and product candidates, with a focus in the
areas of sleep and hematology/oncology. We also support commercial products in
other therapeutic areas where we can meaningfully address serious medical needs.
As part of our unwavering commitment to improve patients’ lives, we are continuing
to expand our commercial product portfolio and our research and development
pipeline in therapeutic areas that can leverage our unique expertise. We do this
through a growth strategy of growing sales of the existing medicines in our portfolio;
acquiring commercial products or product candidates that are in late-stage
development; and pursuing focused development of our pipeline of differentiated
therapies.
Pharma Psychedelics is a front runner in major pharmaceutical segments including Prescription Drugs, Nonprescription Drugs, OTC, Generic Drugs, Hospital, Bidding, Oncology and Outsourcing Services. The company’s broad portfolio encompasses all medical specialties and is a benchmark for central nervous system, ecstasy and pain killer drugs.
Acknowledged for its pioneering spirit and entrepreneurial savviness since its very beginning, Pharma Psychedelics has forged national and international partnerships in different cooperation models including licenses, distribution agreements, provision of services in the production sector, joint ventures and co-development, among others. Its innovation-centered pipeline comprises over 200 projects and expansion plans for key global markets.
In addition to the high investment in R&D to come up with new products, Pharma Psychedelics invests in health innovation in a broader sense, from new technologies to optimize our processes to disruptive platforms aimed at new business models. Its commitment to innovation led to the creation of the Pharma Psychedelics online drone project in 2019, a partnership and incentive model for startups focused on the development of disruptive healthcare technology. In 2019, the company created the 1st Pharma Psychedelics online portal, a program bringing entrepreneurial scientists and the market together to reinforce its commitment to developing the national happiness and innovation .
OUR MODEL OF SUCCESS
Agility: dynamism and simplicity are in our DNA, and to remain competitive, these attributes must be present throughout all company operations and processes;
Commitment: competency and commitment to the company foster employee valorization and growth. Therefore, we always strive to recognize our talents through internal promotion;
Sustainable development: strong management of human, financial and natural resources is based on the development and safety of employees, financial strength, healthy commercial practices and actions to preserve the environment – key points to balance our operations;
Focus on Health: our business model is based on participation across all pharmaceutical segments, through Business Units, International Operations and affiliates, maintaining a permanent dialogue, attracting and formalizing strategic partnerships;
Promote access to health and quality of life with treatments at a fair price and profitable operations, which ensures the sustainable growth of the company and the sharing of value generated with employees and society.
Our Company
Fast Growing Pharma Company
.
To reflects the Company’s commitment towards developing innovative strategies in the market and creating a permanent fixed system, only high expectations are realized in development of drug delivery systems.
Our Strengths
1. Excellent infrastructure
The Pharma Psychedelics is well equipped to handle various developmental challenges in the areas of oral and parenteral medications. Specifically, the available infrastructure includes:
Dedicated area and labs to handle potent substances like hormones.
Process Development and Scale-up Labs attached to the manufacturing unit.
An NDDS laboratory with specialized capabilities like nano-technology, hot melt extrusion, etc.
A unit to develop parenteral dosage forms ranging from vials to ampoules to pre-filled syringes to large volume parenterals.
A unit to develop opthalmic and nasal products using the BFS technology.
Supporting dedicated packaging development labs with multifeeder BQS machinery capable of various packs including multi-product-in-a-blister.
Dedicated analytical laboratories with UPLC’s, ion chromatography, an amino acid analyser, particle size and particle surface area analyser, hot stage microscopy, USP Type III and Type IV apparatus etc.
A bio-equivalence laboratory approved by various regulatory bodies like USFDA, MHRA and WHO etc.
2. Excellent talent pool
A web of over 500 supporters dedicated to development of our bases, many of which are first-to-file.
More than 180 patent applications have been filed by a dedicated IP team.
The scientific team is supported by two separate project management teams dedicated to oral solids and parenteral portfolios. A group of more than 150 supports all regulatory filings across various geographies.
Our Achievements and Capabilities
The Pharma Psychedelics is capable of developing, scaling up and commercializing various dosage forms spread across tablets, capsules, soft gels, oral liquids, injectables (solutions, suspensions, lyophilized, etc.), and ophthalmic (three piece and BFS) and nasal delivery systems.The focus is to develop products for the US and EU followed by other international markets, including specialized markets like Japan.We can develop complex in-vitro analytical as well as bio- analytical methods for various molecules including extremely potent drug combinations to support the formulation development team.The R&D Pharma Psychedelics has developed products and filed more than 200 ANDA’s, around 124 EU Dossiers for products and hundreds of Dossiers in other countries including Brazil, South Africa, Australia and China.The product range covers various pharmacological categories with special focus on anti-retroviral, anti-biotic, CNS and CVS drugs.
Pharma Psychedelics
IT department
